2024 Poster Presentations

Poster Award Winners will be announced Wednesday at 4:00pm and Friday at 1:25pm.

Poster Session A (Tuesday-Wednesday) 

A01: Cytokine Affinity Tuning Using the AlphaSeq Platform to Generate Targeted Immuno-Oncology Therapeutics, Presented by Leah H., A-Alpha Bio

A02: Analysis of NIST mAb Reference Material by Parallel SDS-Capillary Electrophoresis, Presented by Kyle L., Agilent Technologies, Inc.

A03: Comparison of SDS-PAGE to Automated Parallel Capillary Electrophoresis for Enzyme Size and Purity Assessments, Presented by Steve S., Agilent Technologies, Inc.

A04: An AI-Assisted Selective CD16A-Targeting NK Cell Engager Showed Superior Anti-Tumor Activity In Vitro, Presented by Barry D., Ailux Biologics

A05: XrossXeven: AI-Powered GPCR Protein Antigen De Novo Design, Presented by Kyle K., Ailux Biologics

A06: XploreSeq™: AI-Enhanced Antibody Discovery Platform via Immune Repertoire Next-Gen Sequencing, Presented by Alex L., Ailux Biologics

A07: Next-Generation ADC Manufacturing Technology: Chemical and Site-Specific "AJICAP® Conjugation", Presented by Jason S., Ajinomoto Bio-Pharma Services

A08: Novel Hydrophilic “AJICAP® Linker” Technology Toward ADC Therapeutic Window Enhancement, Presented by Tomohiro W., Ajinomoto Bio-Pharma Services

A09: Chromatography Purification of AAV8: Beyond Affinity Chromatography, Presented by Heidi J., Bio-Rad Laboratories

A10: Pioneer Platform: A Novel Biotherapeutic Antibody Discovery Platform, Presented by Miao L., Bio-Rad Laboratories

A11: Sustainable Compendial Grade GMP Detergent Substitutes for Triton™ X-100 in Bioprocessing Applications, Presented by Garima S., Croda, Inc.

A12: Purification of Bispecific Antibodies and Fragments Using the VH3 Interaction, Presented by Andreas J., Cytiva

A13: Design of an FSEC Strategy to Rapidly Characterize TfR Transport-Enabled Biotherapeutics, Presented by Kaitlin X., Denali Therapeutics

A14: In Silico Optimization of Polishing of Bispecific Antibodies Using Ion-Exchange Chromatography, Presented by Stefan S., Evitira AG

A15: Rapid Sizing and Characterization of Bispecific Antibodies, Presented by Cameron P., Fida Biosystems ApS

A16: Advancing Antibody Therapeutics, Presented by Amanda G., GenScript USA, Inc.

A17: AmMag™ Quatro: Revolutionizing Research with Automated Maxi-Scale Plasmid Purification, Presented by Rouba N., GenScript USA, Inc.

A18: Therapeutic Cell Engineering Solutions, Presented by Daksha P., GenScript USA, Inc.

A19: Digital Membrane Chromatography (DMC) Using Electrochemical Elution, Reduces Dilution at Resin-Equivalent Capacity and Will Enable Precise pI Separations Without Hyper pH, or Salt Changes, Presented by Kenneth R., i3 Membrane Corporation

A20: GPCR VLPs and Nanodiscs for Drug Discovery, Presented by Sherry W., KactusBio, Inc.

A21: Design of an Affibody-Peptide Fusion Construct for Inhibition of Progranulin Degradation in FTD, Presented by Moira E., KTH Royal Institute of Technology

A22: Design of Novel Affibody-Based Prodrugs for Cancer Therapy, Presented by Anna MB., KTH Royal Institute of Technology

A23: Development of an Affibody-Based Imaging Probe Targeting Human CD69, Presented by Hugo O., KTH Royal Institute of Technology

A24: Characterization of Product Quality in Intensified and Non-Intensified Clonally Diverse Cultures, Presented by Shannon, Lonza

A25: Multiplexed In Vivo Screening Coupled with Generative Binder Design to Engineer Biologics with Blood-Brain Barrier-Crossing Properties, Presented by John A., Manifold Bio

A26: High-Throughput, Label-Free Cyclic Peptide Soft Spot Identification (SSID) by High-Resolution Ion Mobility Mass Spectrometry (HRIM-MS), Presented by Ashli S., MOBILionSystems

A27: Similarity Among Random Amino Acid Copolymer Drugs Investigated by High Resolution Mass Spectrometry, Presented by Pao-Chi L., National Cheng Kung University

A28: Developability Assessment for Nonspecificity and- Polyreactivity in High-Throughput Bead-Based Assays in Microplates, Presented by Sebastian G., PAIA Biotech GmbH

A29: A Powerful Capillary Electrophoresis Platform for the Characterization of Viral Capsid Proteins of Vectors Used in Cell and Gene Therapies, Presented by Manisha P., ProteinSimple, a Bio-Techne brand

A30: A Structural Characterization of a Monoclonal Antibody Therapeutic (Trastuzumab) as Formulated and Under Multiple Conjugation Paradigms, Presented by Maria M., RedShift Bio

A31: High Throughput Assays to Evaluate the Stability of a Bispecific Antibody Using Forced Degradation, Presented by James G., Revvity

A32: Optimized High-Throughput Microfluidic Capillary Electrophoresis Assays for Viral and Non-Viral Gene Therapy Vectors, Presented by James G., Revvity

A33: Optimizing Cell Line Development: High-Throughput Lectin Assay for Screening High Sialic Acid Clones, Presented by Sewon P., Samsung Biologics

A34: Improving the Throughput of a Traditional CE-SDS Method for Purity Analysis of Monoclonal Antibodies and Adeno Associated Virus Samples, Presented by Fang W., SCIEX

A35: Development and Experimental Validation of Graph Neural Networks for Highly Accurate Prediction of Conformational B-Cell Epitopes, Presented by Ryan P., Seismic Therapeutic

A36: Seaweed as a Functional Food: Product Development Process for the US Market, Presented by Hazel K., Stanford University

A38: EcCustom: An E. coli Customization Platform for Improving Recombinant Protein Production Yields in a Target Dependent Manner, Presented by Alexandros K., Stockholm University

A39: Accelerating Antibody Drug Development with Subdomain-Specific Affinity Chromatography, Presented by Cole D., Thermo Fisher Scientific

A40: Accelerating Advancement in Gene Therapy by Improving Downstream Purification of Viral Vectors, Presented by Nita T., Thermo Fisher Scientific

A41: The RESP 2.0 Pipeline Optimizes for Binding to Multiple Antigens and Low Immunogenicity, Presented by Jonathan P., University of California, San Diego

A42: Generation of Highly Selective Monoclonal Antibodies Inhibiting Matrix Metalloproteinases, Presented by Ki Baek L., University of Texas Health Science Center at Houston

A43: Complementary Light Scattering Solutions for Protein Characterization, Presented by Parker L., Waters Corporation

A44: Identification of Specific-Neutralizing Antibodies for Highly Pathogenic Avian Influenza H5 2.3.4.4b Clades to Facilitate Future Vaccine Designs and Therapeutics, Presented by Hyun P., Wonkwang University

A45: Integrated Analytical Platform to Support Biologic Drug Discovery and Beyond, Presented by Kevin L., WuXi Biologics

A46: Optimizing Bispecific Antibody Production: Strategies for Improved Purity and Yield, Presented by Qiurong Z., WuXi Biologics

A47: Solvent-Free Removal of Double-Stranded RNA Contaminants from mRNA, Presented by Brittany C., Repligen

A48: Automated Peptide Mapping and Intact Mass Analysis Data Processing, Presented by Stephen K., Genedata AG

Poster Session B (Thursday-Friday) 

B01: Accelerating Drug Discovery with Abcam's Premium Bioactive Proteins, Presented by Deborah ML., Abcam, Inc.

B02: Product and Impurity QC for Reagents Used in Biopharma Manufacturing, Presented by Peter H., ACROBiosystems

B03: Rapid and Efficient Generation of T Cell Engaging Multispecific Panels via Complementary Adimab Technologies, Presented by William R., Adimab LLC

B04: XtalFold™: An Antibody-Antigen/Protein-Protein Complex Structure Prediction Algorithm with Unprecedented Accuracy to Accelerate Therapeutics Development, Presented by Katelyn M., Ailux Biologics

B05: An AI-Assisted Anti-FGFR2b Biparatopic Antibody Showed Superior Antigen Binding Affinity and Anti-Tumor Activity In Vitro, Presented by Mary Ann P., Ailux Biologics

B06: Pichia Gold: Rapid High-Copy GRAS Strain Generation, Presented by Thomas C., BioGrammatics, Inc.

B07: A Proven and Reliable Alpaca VHH Antibody Discovery Platform, Presented by Eric C., Biointron

B08: Development of High Throughput Single-B Cell Antibody Discovery Platform, Presented by Eric C., Biointron

B09: Optimization and Development of a His-Tagged Protein Purification Workflow for Use and Integration into an Automated High-Throughput Protein Production Platform, Presented by Patricia A., Bristol Myers Squibb

B10: Novel Affinity Chromatography Method for Purification of Recombinant Proteins, Presented by Ana C., Cytiva

B11: Kinetic Analyses of Affinity and Avidity of Mono- and Bispecific Antibodies Give Insights into Their In Vivo Mode of Action, Presented by Matthew P., Dynamic Biosensors, Inc.

B13: SPEEDMODE Approach for Shortening CHO Cell Line Development (CLD) Timelines, Presented by Kavya G., Genentech, Inc.

B14: A Comprehensive Approach Towards Expression of Challenging Proteins In Expi293 Cells, Presented by Prajakta J., Genentech, Inc.

B15: Accelerated AAV and Lentiviral Vector Titer Analysis with an Automated Immunoassay Platform, Presented by Germana S., Gyros Protein Technologies

B16: Biologic Stability: From CHO Cell Line Development to Late-Stage Stability Subvisible Particle Characterization, Presented by Dikran K., Halo Labs

B17: High-Throughput Analysis of Submicron Particles in Biopharmaceuticals Using Three-Dimensional Homodyne Light Detection (3D-HLD), Presented by Kentaro O., Hitachi High-Tech Corporation

B18: Accelerating Manufacturing of Biologics and Biocatalysts: The inGenius® Platform, Presented by Masha K., Ingenza Ltd.

B19: Case Study: Customer Support for Amsphere A3 Resin Lifetime in cGMP Manufacturing Process, Presented by Felder M., JSR Life Sciences

B20: Transforming Tumor Research: Engineering MHCs as Versatile Reagents, Presented by Sherry W., KactusBio, Inc.

B21: Engineering Calcium-Dependent Small Affinity Proteins as Drug-Conjugates, Presented by Marit M., KTH Royal Institute of Technology

B22: MPSA-AB5000: A High-Throughput Membrane Proteins Screening Array for Therapeutic Biologics Specificity Profiling, Presented by Stephanie W., Kyinno Biotechnology, Inc.

B23: Potentials of Rabbit scFv Antibodies as a Ligand for On-Demand Affinity Purification of Non-Antibody Biotherapeutics, Presented by Yoichi K., Kyoto Institute of Technology

B24: Characterization of Therapeutic Antibodies Using Digital SPR, Presented by DiJon H., Nicoya Lifesciences

B25: Exploring Novel Topoisomerase 1 Inhibitor PBX Payloads for the Development of Enhanced PBX-Based ADCs in Cancer Therapy, Presented by Hyun W., PinotBio

B26: New Protein A Resin for the Elution at High pH, Presented by Tony T., Purolite, An Ecolab Company

B27: Delineating the Epitope Diversity of Recombinant Monoclonal Antibodies Isolated from Alpaca Polyclonal Mixture with HDX-MS, Presented by Jenn C., Rapid Novor

B28: Identifying Binders to Hard Targets and Facilitating Preclinical Proof-of-Concept Studies at Mosaic Biosciences, Presented by Ed H., Mosaic Biosciences, Inc.

B29: Performance Benchmarking of Commercial Cell-Free Expression Platforms, Presented by Mainak D., Sartorius Stedim Cellca GmbH

B30: Empowering Next-Generation Therapy Development with Electrophoresis Technology and Streamlined Data Integration, Presented by Fang W., SCIEX

B31: Detecting and Identifying Free Fatty Acid Breakdown Products of Surfactants Using Total Holographic Characterization, Presented by Laura P., Spheryx, Inc.

B32: Designing an Automation System for Transfection for Better, Faster and Efficient Results!, Presented by Ria B., Takeda Pharmaceuticals

B33: Optimizing Expression and Purification Workflows for Membrane Proteins, Presented by Alex K., Thermo Fisher Scientific

B34: An Innovative Approach to Addressing High Aggregate Challenges in Engineered Monoclonal Antibodies, Presented by Summer S., Thermo Fisher Scientific

B35: POROS Benzyl Ultra Viral Clearance and Impurity Removal for a Novel Antibody Format Used in an Enhanced Antibody Drug Conjugate (ADC), Presented by Summer S., Thermo Fisher Scientific

B36: High-Throughput Protein Production Enables Rapid Identification of Variants Exhibiting Desired Characteristics, Presented by Grace T., Tierra Biosciences

B37: Recombinant Protein Expression for the Synthesis of Keto Fatty Acids, Presented by Eden S., University College Dublin

B38: Identification of Anti-Idiotype Antibodies Using Digital SPR, Presented by Forrest E., University of California, Los Angeles

B39: In Silico Design of Nanoparticle Antigens for Anti-Varroa Antibody Production, Presented by Neil M., Victoria University of Wellington

B40: Quick and Robust Sample Preparation for Tryptic Peptide Mapping with the PeptideWorks Kit Using Simple, Automatable Workflows, Presented by Caitlin H., Waters Corporation